These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16315230)

  • 1. Anthrax vaccine powder formulations for nasal mucosal delivery.
    Jiang G; Joshi SB; Peek LJ; Brandau DT; Huang J; Ferriter MS; Woodley WD; Ford BM; Mar KD; Mikszta JA; Hwang CR; Ulrich R; Harvey NG; Middaugh CR; Sullivan VJ
    J Pharm Sci; 2006 Jan; 95(1):80-96. PubMed ID: 16315230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable dry powder formulation for nasal delivery of anthrax vaccine.
    Wang SH; Kirwan SM; Abraham SN; Staats HF; Hickey AJ
    J Pharm Sci; 2012 Jan; 101(1):31-47. PubMed ID: 21905034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.
    Jones RM; Burke M; Dubose D; Chichester JA; Manceva S; Horsey A; Streatfield SJ; Breit J; Yusibov V
    Vaccine; 2017 Oct; 35(41):5463-5470. PubMed ID: 28117174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
    Huang J; Mikszta JA; Ferriter MS; Jiang G; Harvey NG; Dyas B; Roy CJ; Ulrich RG; Sullivan VJ
    Hum Vaccin; 2007; 3(3):90-3. PubMed ID: 17375001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.
    Mikszta JA; Sullivan VJ; Dean C; Waterston AM; Alarcon JB; Dekker JP; Brittingham JM; Huang J; Hwang CR; Ferriter M; Jiang G; Mar K; Saikh KU; Stiles BG; Roy CJ; Ulrich RG; Harvey NG
    J Infect Dis; 2005 Jan; 191(2):278-88. PubMed ID: 15609239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.
    Maa YF; Ameri M; Shu C; Payne LG; Chen D
    J Pharm Sci; 2004 Jul; 93(7):1912-23. PubMed ID: 15176078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
    Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
    Jendrek S; Little SF; Hem S; Mitra G; Giardina S
    Vaccine; 2003 Jun; 21(21-22):3011-8. PubMed ID: 12798645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
    Berthold I; Pombo ML; Wagner L; Arciniega JL
    Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
    Garmise RJ; Staats HF; Hickey AJ
    AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.
    Keitel WA
    Expert Rev Vaccines; 2006 Aug; 5(4):417-30. PubMed ID: 16989623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.
    Maa YF; Zhao L; Payne LG; Chen D
    J Pharm Sci; 2003 Feb; 92(2):319-32. PubMed ID: 12532382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR; Cui Z
    Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
    Domínguez-Castillo RI; Verma A; Amador-Molina JC; Sirota L; Arciniega JL
    Biologicals; 2013 Mar; 41(2):111-4. PubMed ID: 23137818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
    Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
    J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with protective antigen of Bacillus anthracis induces a long-term immunological memory response.
    Woo SJ; Kang SS; Park SM; Yang JS; Song MK; Yun CH; Han SH
    Mol Immunol; 2015 Oct; 67(2 Pt B):492-500. PubMed ID: 26278659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.